A randomized, double-blind, controlled study on the treatment of stable vitiligo with compound Honghuabuji granules

Phase 1

Recruiting

• Conditions: vitiligo

• Registration Number: ITMCTR2100004855
• Lead Sponsor: Shanghai Dermatology Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients who are clearly diagnosed as vitiligo, and those who have been diagnosed as blood stasis syndrome by Chinese medicine;
2. Patients aged 18 to 60 years;
3. Mainly confined and sporadic;
4. In order to accurately compare the test results, the hypopigmented area of all patients in this test is <= 10% of the total body surface area;
5. No systemic or topical glucocorticoid or immunosuppressant treatment or withdrawal of the drug for more than 3 months within 3 months;
6. Patients with leukoplakia that have not expanded within 6 months and are in a stable phase;
7. Patients who agree to take pictures of the skin lesions and can complete the treatment and follow-up on time.

Exclusion Criteria

1. Pregnant and lactating women;
2. System or topical vitiligo drug treatment within 3 months;
3. Patients who are allergic to tacrolimus ointment and compound Honghuabuji granules.
4. Patients with severe heart, liver, kidney and other system diseases;
5. Patients who withdraw halfway and have incomplete information.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
White spot area;

Secondary Outcome Measures

Name	Time	Method
Vitiligo impact scale-22;TCM symptoms scale;